PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16050953-8 2005 N-terminal extension by means of glucitol addition is more beneficial to bioactivity of GIP than it is to GLP-1. Sorbitol 33-41 gastric inhibitory polypeptide Mus musculus 88-91 9518868-1 1998 This study investigates the effects of gastric inhibitory polypeptide (GIP) and glycated GIP (glucitol adduct of GIP) on glucose uptake and metabolism in muscle. Sorbitol 94-102 gastric inhibitory polypeptide Mus musculus 89-92 9518868-1 1998 This study investigates the effects of gastric inhibitory polypeptide (GIP) and glycated GIP (glucitol adduct of GIP) on glucose uptake and metabolism in muscle. Sorbitol 94-102 gastric inhibitory polypeptide Mus musculus 89-92 10828847-8 2000 Most prominent effects were observed in the former group where plasma glucose values at 60 min together with the area under the curve (AUC) for glucose were significantly lower following GIP (AUC, 874+/-72 mmol/l.min; P<0.01) or Tyr(1)-glucitol GIP (770+/-134 mmol/l.min; P<0.001) as compared with administration of glucose alone (1344+/-136 mmol/l.min). Sorbitol 239-247 gastric inhibitory polypeptide Mus musculus 187-190 10828847-9 2000 This was associated with a significantly greater and more protracted insulin response following Tyr(1)-glucitol GIP than GIP (AUC, 491+/-118 vs 180+/-33 ng/ml.min; P<0.05). Sorbitol 103-111 gastric inhibitory polypeptide Mus musculus 112-115 10828847-10 2000 Administration of Tyr(1)-glucitol GIP also enhanced the glucose-lowering ability of 50 units/kg insulin (218.4+/-30.2 vs insulin alone 133.9+/-16.2 mmol/l.min; P<0.05). Sorbitol 25-33 gastric inhibitory polypeptide Mus musculus 34-37 10828847-11 2000 These data demonstrate that Tyr(1)-glucitol GIP displays resistance to plasma DPP IV degradation in a commonly used animal model of type 2 diabetes, resulting in enhanced antihyperglycaemic activity and insulin-releasing action in vivo. Sorbitol 35-43 gastric inhibitory polypeptide Mus musculus 44-47